Apollo Therapeutics is a portfolio biotech company that develops a broad range of drug programs to generate value for its stakeholders. It has a diversified clinical-stage portfolio of assets focused on high-value markets, with over 20 programs in its core areas of biological focus, including cell signaling, cell stress response, and immunology.

Apollo Therapeutics

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease. 

Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners.

Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA. 

For more information, please visit our website at www.apollotherapeutics.com

UCLB

Rock Springs Capital

Patient Square Capital

M&G Plc

Reimagined Ventures

UCL Technology Fund

Our CEO Richard Mason will be presenting an overview of Apollo Therapeutics at the Evercore ISI 2024 Emerging Biotech Conference tomorrow (Thursday, February 29) at 10:45 – 11:15 ET.
#biotech  #conference 


Apollo Therapeutics will be attending the Cowen Inc. 44th Annual Health Care Conference in Boston, US next week from March 4-6. Our CEO Richard Mason and CFO Jamie Heath will be hosting one-on-one meetings on Tuesday, March 5 - meeting slots can be booked via Cowen or please do let us know directly if you would like to connect at the conference.
 
We look forward to seeing you there!
 #biotech #conference 


We are delighted to have completed the second close of our Series C financing in December 2023, bringing the total raised in this round by the Company to $260m. 
 
The Series C financing was led by Patient Square Capital and included participation by multiple new investors including M&G plc and two of the largest US public pension plans, along with existing investors including Rock Springs Capital.
 
This fundraise means we can continue to progress our broad and diversified pipeline of over 20 uncorrelated therapeutic programs, with multiple assets about to enter the clinic in early 2024.
	 
#seriesc #biotech #fundraising 

COM:APOLLOTHERAPEUTICS

Apollo Therapeutics

market

industry

website

crunchbase

linkedin

founding date

investor of

Metrics